1621 - Amendment to MBS Item 73344 for c-ROS proto-oncogene 1 fluorescence in situ hybridisation testing to identify ROS1, to determine patient eligibility for entrectinib under the Pharmaceutical Benefits Scheme

Page last updated: 16 June 2020

Application Detail

Description of Medical Service

The proposed service is testing of the ROS1 gene rearrangement by fluorescence in situ hybridisation (FISH) to determine eligibility to access entrectinib under the PBS.

This submission requests a minor amendment to MBS item 73344 be made allowing its use to determine eligibility to access crizotinib or entrectinib under the PBS.

Description of Medical Condition

Non-small cell lung cancer.

Reason for Application

Amendment to MBS item

Medical Service Type


Previous Application Number/s

Not Applicable

Associated Documentation

Application Form


Consultation Survey


PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 436 KB)
Public Summary Document (Word 151 KB)

Meetings for this Application






3 April 2020